Fig. 5.

TAT/CDT/ICB trimodal treatment for inhibiting tumor cell rechallenge. (a) Schematic illustration of the combination therapy to generate anticancer immune memory and inhibition of cancer recurrence. (b) Growth curves of the rechallenged tumors after different treatments. Data are mean ± s.d. (n = 5). (c) Body weight of balb-c mice. Data are expressed as mean ± SD (n = 5). (d) Photographs of ²¹¹At-ATE-MnO₂-BSA + anti-PD-L1 cured mice and untreated mice receiving CT26 tumor cells. (e) Representative flow cytometric analysis images and corresponding quantification results of the percentage of central memory T cells (TCM) and effector memory T cells (TEM) of splenic lymphocytes of different groups 15 days after CT26 tumor cell rechallenge (n = 3). (f) Expression levels of serum cytokines including TNF-α and IFN-γ from mice after the secondary tumor rechallenge (n = 3). P values were calculated by t-test (*P<0.05, **P < 0.01 and ***P < 0.001)